High-throughput Drug Screening in HepG2 Cells
Corresponding Organization :
Other organizations : St. Jude Children's Research Hospital, University of Cincinnati, Cincinnati Children's Hospital Medical Center
Variable analysis
- Drugs used include cisplatin, gemcitabine, vincristine, triapine, MK1775, doxorubicin, sorafenib, SN-38, deferoxamine mesylate, KU60019
- Cell Titer Glo (CTG) viability assay conducted after 72 h of drug treatment
- Cell line: HepG2 or HB214
- Seeding density: 1500 cells/well
- Seeding volume: 30 μl
- Incubation time: 24 h before drug addition
- Incubation time with drugs: 72 h
- CellTiter-Glo 2.0 reagent added in 1:1 v/v ratio
- Incubation time with CellTiter-Glo 2.0: 30 mins
- Plate reading: Synergy H4 plate reader for luminescence
- Data analysis: Prism software, version 9 (GraphPad)
- Dose effect curves calculated using Prism software
- Drug combinations analyzed using SynergyFinder2.0
Annotations
Based on most similar protocols
As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!